- Home
- LXEO vs EDD Comparison
LXEO vs EDD Comparison
Compare LXEO & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LXEO | EDD |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance Companies |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.9M | 361.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXEO | EDD |
|---|---|---|
| Price | $5.86 | $5.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $18.44 | N/A |
| AVG Volume (30 Days) | ★ 613.5K | 325.7K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.43 | $4.84 |
| 52 Week High | $10.99 | $6.18 |
Technical Indicators
Market Signals| Indicator | LXEO | EDD |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 50.23 |
| Support Level | $5.54 | $5.44 |
| Resistance Level | $6.08 | $5.70 |
| Average True Range (ATR) | 0.32 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 23.85 | 36.51 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.